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INTRODUCTION.
In a previous  communication, Ellis and I1 reported that the serum of patients
who  were  treated  intravenously  with  salvarsan  or neosalvarsan  had  a  definite
spirocheticidal  action.  This  action was increased by heating the  serum at 56 0C.
for one-half  hour.  By an indirect  method it was shown,  first, that  the  heat de-
stroyed  some  inhibitory  substance  in  the  serum,  and,  second,  that  it  directly
increased  the action  of  the  serum-salvarsan  mixture.  The  beneficial  effects  of
intraspinal injections of serum in the treatment  of syphilis of the central  nervous
system  have been attributed  in part to this  spirocheticidal  substance.  Because
of the variable quantities  of salvarsan  in  the serum of patients after intravenous
injections  of  the  drug, Ogilvie2 has  suggested  a  method  for  the  preparation  of
salvarsanized  serum  in which  a  small  quantity  of  faintly  alkaline  solution  of
salvarsan  is  added  to serum, the mixture incubated  and  heated at 560C. for one-
half  hour.  The  object  of  the  present  work  was  to  study the  spirocheticidal
effect  of  serum  salvarsanized  in vitro.
Following  our first  communication,  StUhmer3 showed that the serum  of salvar-
san-treated  rabbits had  a trypanosomicidal action which was  markedly increased
by heating.  He  also  showed  that heating  increased  the  intensity of  the  para-
dimethylamidobenzaldehyde  color reaction  for salvarsan,  and  that the  intensity
of the  color reaction  and the trypanosomicidal  power were more or less parallel.
However,  by studying  the serum daily for 10  days  following  the intravenous  in-
jection of salvarsan,  he demonstrated that the trypanosomicidal  action of  heated
serum persisted several days after the color reaction  had disappeared.  He4 next
showed that the trypanosomicidal  action  of  the  serum  of salvarsan-treated  rab-
bits persisted longer than that of neosalvarsan-treated  rabbits, and that the serum
of rabbits treated intramuscularly with salvarsan  had very little action.  Ehrlich
'Swift,  H. F., and Ellis,  A. W. M.,  J. Exp. Med.,  1913, xviii, 435.
2  Ogilvie, H. S., J.  Am. Med. Assn.,  1914,  xiii,  1936.
3 Stiihmer,  A., Manch. med. Woch.,  1914,  lxi,  745.
4 Stiihmer, Munch. med. Woch.,  1914, Ixi,  1101.
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suggested  that the effect  of heat was to break up a  loose  combination  which had
taken place between  the salvarsan and some substance  in the serum, thus setting
free  the salvarsan  which  acts on  the trypanosomes  or spirochetes;  but Sttiihmers
attributed  the  increased action  of heated  serum  to an increased  oxidation.  He
finally  studied  the effect  of  oxidation  and  reduction on  the  salvarsanized  rabbit
serum and showed that oxidation did  not increase the trypanosomicidal  power of
either  unheated  or  heated  serum,  and  also  that  reduction  with  weak  sodium
hydrosulphite  solution  did  not decrease  the power  of the unheated  serum.  Re-
duction,  however,  did  affect  the  heated  serum  by  removing  the  increased  try-
panosomicidal action which  had been produced by heating.  In  other words, the
reduction caused the heated serum to act in the same manner as unheated  serum.
As  Stihmer's  experiments  were  not  performed  with  diminishing  dilutions  of
serum,  but with  serum  obtained  on  successive  days after  the  administration  of
salvarsan, the exact relation of heating,  oxidation, and reduction are not entirely
clear.
Methods.
In the present  study a strain  of Spirochceta duttoni, propagated in
white mice,  has been  employed.  The suspension  for performing  the
test was  prepared by  bleeding a well infected mouse  into warm  nor-
mal saline solution,  and diluting with normal saline  solution until the
required  number  of spirochetes  per field was obtained.  Equal quan-
tities  of  this suspension  and the dilution  of serum  to be  tested were
mixed  thoroughly  and  incubated  at  37°C.  for  1 hour.  1 cc. of the
mixture,  representing  0.5  cc.  of  the  spirochete  suspension,  was  in-
jected  into mice  intraperitoneally.  The blood  of  the  infected  mice
was  examined  daily  with  the  dark-field  microscope.  The  intensity
of  the  subsequent  infection  is  indicated  by  the  average  count  of
twenty fields, as shown in the protocols.  The salvarsanized serum was
prepared  as  follows: A  slightly  alkaline  watery  solution of  salvarsan
was diluted to 1: 2,000 with 0.5 per cent  saline solution.  One part of
this was added  to nine parts of serum, making a dilution  of  1:20,000,
and from  this the subsequent dilutions were made with normal serum,
or normal salt solution,  as the experimental  conditions  required.
EXPERIMENTAL.
The  serum-salvarsan  mixture  prepared  in  vitro  had  a  definite
spirocheticidal  action.  This  point  was  previously  demonstrated  by
5 Stiihmer, Milnch. med. Woch.,  1914, lxi, 2338.
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TABLE  I.
Comparison of Serum Salvarsanized in Vitro  with Serum of a Salvarsan-Treated
Patient.
Mouse.
Al
A2
A3
A4
A5
B1
B2
B3
B4
B5
C1
Dl
D2
El
F1
F2
Control.
S1
Dilution.
Salvarsan.
1:40,000
1:80,000
1:160,000
1:320,000
1:640,000
1:40,000
1: 80,000
1:160,000
1:320,000
1:640,000
Patient's
serum.
1:1
1:1
1:2
1:1
1:1
1:2
1:1
Salvarsan  per
cc.  of serum.
mg.
0.025
0.012
0.006
0.003
0.0015
0.025
0.012
0.006
0.003
0.0015
Heated
or unheated.
Unheated.
4
Heated.
Heated.
Unheated.
Heated.
Day after injection.
0
=w
0
+
=I w
2
0
+
+
++
++
0
0
+
+
+
++
++
++
3
+++
+++
+++
+++
+++
+++
0
+
4
0
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
N=w  indicates  between 1 and 19 spirochetes  in 20 fields;  , 1 per field;  +, 2-10
per field;  + +,  11-20 per field;  + + +,  20-50 per field;  + + ++,  more  than  50
per field.
Dilutions of salvarsan  in normal serum  were  made,  incubated,  and each  dilu-
tion divided  into  two  portions;  one  of  each  portion  was  heated  at  560C.  for
one-half  hour.  A  syphilitic  patient  weighing  71  kilos received  0.3  gm.  of  sal-
varsan  intravenously  (Sera  C  and  D),  and  another  weighing  68  kilos  received
0.5 gm.  (Sera  E and  F).  Blood  was  taken  from  each  after  1 hour,  allowed  to
coagulate,  centrifugalized,  and  the  serum  removed  immediately.  The  serum
from  each was  divided  into two  portions,  one  of  which  was heated  at 56°C.  for
one-half  hour, and  then  diluted as  indicated.  The  spirochetal  suspension,  con-
taining  between  six  and  eight  spirochetes  per field  was mixed  with  the  various
sera; it was then incubated  for 1 hour and injected into mice.
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Gonder.6 Heating  the  mixture at  560C.  for one-half hour  increased
this  action.  The  effect  of  heating  was  studied  in a  series  of  seven
experiments; four times the heating doubled the strength of the serum,
twice it quadrupled  it, and once  increased it eightfold.  In  terms  of
absolute amounts of salvarsan in the heated serum,  in three  instances
the  spirocheticidal  action  was  complete  in a  concentration  of  0.025
mg.,  in  three  others  of 0.012  mg.,  and  once  of 0.006  mg.  per  cc.  of
serum.  This  variation  was  probably  due  to  the  difference  in  the
number  of  spirochetes  in  the suspension  in  the several  experiments.
In Experiment  1 (Table  I)  the  heated  serum  salvarsanized  in vitro
was more effective  in a dilution of  1: 80,000 than the patient's serum,
and  the  heating  had  less  relative  influence  on  the  patient's  serum.
It  should  be noted here  that the serum  was  removed  from  the  clot
within an hour of the time the patient was bled.  In this respect this
part of the  experiment  differs  from  those  previously  reported.  In
our  earlier  work the  serum  always  stood  over  night  before  separa-
tion  from  the  coagulum.
Although  the spirocheticidal  action  of  the unheated  serum  which
was  separated  immediately  was  only  slightly  less  than that  which
stood on the clot over night, a greater difference was noted between the
two sera after they were heated.  Heating increased the action of the
serum which had been in contact with the clot over  night much more
than it did  the serum removed from the clot immediately (Table II).
Six different  experiments were  performed  with  the serum of patients
obtained  after  salvarsan  treatment.  In  four  in  which  the  serum
was  separated  immediately,  the increase  in spirocheticidal  action  of
heated serum was  considerably  less marked than in  two in which  the
serum was  removed  from  the clot  24 hours  after the bleeding  (Table
VII,  G  and H).
After the demonstration  of this point with the serum of  salvarsan-
treated patients,  it seemed desirable  to determine whether the  serum
from  blood  salvarsanized  in vitro  would  act  in  the  same  manner.
The  results  of  this  experiment  are  shown  in  Table  III.  Here  the
two  unheated  sera  were  again  spirocheticidal  in  the  same  dilution,
although  Serum  A  in  1:2  dilution  inhibited  the  infection  2 days
'Gonder,  R., Z. Immunititsforsch., Orig., 1914,  xxi, 309.
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TABLE  II.
Comparative Effect  of Immediate Separation  from Clot and Separation after Stand-
ing 24  Hours, with  Serum from  Salvarsan-Treated Patient.
Head  orDay  after injection.
Mouse.  Dilution  of serum.  Heated  or unheated.
1  2  3  4
Separated  immediately.
Al  1:1  Unheated.  +  +  +++  Dead.  -
A2  1:2  "  "  +  +++  - w  0
B1  1:1  Heated.  0  - ++  +++
B2  1:2  +  +  0
B3  1:4  "  w  +  +  0
Separated after 24  hrs.
C1  1:1  Unheated.  +  ++  -+++  O
C2  1:2  +  +++  +  0
DI  1:1  Heated.  0  -w  +  'w
D2  1:2  CC  0  -w  +  0
D3  1:4  "  w  W  w 
Control.
S1  Injected immediately.  +  0+  +0  + 
A patient  weighing  65 kilos received  0.4 gm.  of salvarsan  intravenously.  50
cc.  of blood  were  withdrawn  after  one-half  hour,  allowed  to coagulate,  centri-
fugalized,  and  10  cc.  of  serum  pipetted  off.  The  remainder  of  the  serum  was
allowed  to stand  on  the clot  over night,  after which  it was  centrifugalized  and
pipetted  off.  Each serum was divided into  two lots,  and  one of  each heated at
56°C. for one-half  hour.  Dilutions of each series  were made  with normal saline;
the  spirochetal  suspension  containing  from four to five  spirochetes  per field  was
added; it was then incubated for 1 hour and injected into mice.
longer  than did  Serum  C  in the same solution.  When  the  two  sera
were  heated,  however,  the one  that was  immediately  removed  from
the  clot  was more  potent  than  the one  that stood  on  the clot  over
night.  This is  the opposite  of  what  occurred  with  patient's  serum.
The explanation of this difference  is not clear,  but it is suggested that
the  salvarsan  undergoes  some  change  while  circulating  in  the body
which  it does  not undergo  when it  is  mixed with  blood in  the  test-
tube.  This may be  due to  the fact  that in the body it is in contact
with  blood in  the fluid  condition  for a longer period, hence oxidative
conditions are more complete;  or that contact  with the tissues brings
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TABLE  III.
Comparative Effect of Immediate Separation  from Clot and Separation  after Stand-
ing 24  Hours with  Serum from  Blood Salvarsanized in  Vitro.
0
0
0
0
0
O
2
Dead.*
0
0
0
-4- W
Day  after injection.
Heated  or -.  .4Dn
unheated.
Unheated.
Heated.
cc
it
Unheated.
ic
cc
Heated.
{e
Cc
1  :  1  6  0  0~~~~9
1:16
Serum  separated
after  standing
over night.
1:1
1:2
1:4
1:8
1:2
1:4
1:8
1:16
* Died from mouse  typhoid infection.
2 cc. of a 1:2,000 dilution  of salvarsan were mixed with 18 cc.  of freshly drawn
human blood.  This was divided into two equal portions and allowed to coagulate.
The first was then centrifugalized  and the serum removed  from the clot; the sec-
ond was  allowed  to  stand over  night  in the  ice  box,  after  which it was  centrif-
ugalized  and  the  serum  removed.  Both  lots  of  serum  were  divided  into  two
portions,  and  one  of each  was  heated  at 56C. for  one-half  hour.  Dilutions  of
each  of the four  series were made with  normal saline  solution.  The  suspension
of  spirochetes, containing  three  to  four  spirochetes  per  field,  was added; it was
then incubated  for 1 hour and injected  into mice.
about some change in it which is not effected in the test-tube.  From
this  point  of  view,  at  least,  the  use  of  serum of  salvarsan-treated
patients seems justified.
w
0
0
0
0
0
0
0
0
"~w
+
0
+
0
0
++
Serum  separated
immediately.
1:1
1:2
1:4
1:8
1:2
1:4
1:8
+
0
0
+
0
++ w
++
3
0
++
++
0
0
--
++
0
-aw
++
0
+++
7
0
0
0
0
0
0
0
0
0
0
0
'0
0
}
Al
A2
A3
A4
B2
B3
R4
B5
C1
C2
C3
C4
D2
D3
D4
D5
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0
0
0
0
0
0
=F=W
0
0
0
0
0
0
0
0
0
0
0
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TABLE  IV.
Comparison of Serum Salvarsanized in Vitro with Serum from Blood Salvarsanized
in  Vitro.
Day after injection.
Mouse.  Dilution of serum.  unheated  or.
I  2  3  4
Salvarsanized  serum.
Al  1:1  Unheated.  0  0  0  0
A2  1:2  . w  +  0
A3  1:4  "  ++  +  0
A4  1:8  i  +  ++  +  Dead.
BI  1:1  Heated.  0  0  0  0
B2  1:2  "  0  0  0  0
B3  1:4  I  0  0  0  0
B4  1:8  "  ew  +  O
B5  1:16  ,  "  w  +  +  w
Serum  from  salvar-
sanized  blood.
C1  1:1  Unheated..  0  -w  - w  +
C2  1:2  . 0  "-w  +  w
C3  1:4  "  - w  ++  o  0
C4  1:8  +  ++  +  0
D1  1:1  Heated.  0  0  0  0
D2  1:2  . 0  0  0  0
D3  1:4  -w  ++  0
D4  1:8  "w  +  ++  0
D5  1:16  "  +  ++  +++  +
Controls.
S1  Injected immediately.  - w  ++  Dead.
S2  After  1 hr.  incubation  with  nor-
mal sera.  +  + +  -"
1 cc.  of a 1: 2,000  dilution of salvarsan  was mixed with 9 cc. of normal human
serum  (making  a dilution  of 1:20,000),  incubated  for  1 hour,  divided  into  two
portions,  A, unheated,  and  B,  heated,  at  560C.  for  one-half hour.  1 cc.  of the
same  salvarsan dilution was  mixed with 9 cc.  of freshly drawn blood,  incubated
for  1 hour, centrifugalized,  and the serum pipetted  off and divided into  two por-
tions,  C, unheated, and D,  heated  the same as B.  The various  series  were then
diluted  with normal  saline  solution;  the spirochetal  suspension,  containing  eight
to  ten  spirochetes  per  field,  was  added;  it  was  then  incubated  for  1 hour and
injected  into mice.SERUM  SALVARSANIZED  IN  VITRO
Experiment 4 (Table  IV) was devised  to determine whether a more
potent serum resulted  from  the addition  of  salvarsan  to  serum  or to
blood.  Both  were  prepared  on  the  same  day  and  tested within  2
hours  of  the time  of preparation.  In both the unheated  and  heated
condition  the  serum  prepared  by  the  direct  addition  of  salvarsan
was more spirocheticidal  than the serum  from blood to which salvar-
san  had  been  added.
The demonstration that heating increased the spirocheticidal  action
of  the  salvarsan-serum  mixture  permitted  a  study  of  the  effect  of
heat on each  component  of the mixture.  This experiment  confirmed
by a direct method what was previously demonstrated by an indirect
method, that part of the action of the heat was to remove some inhib-
itory  substance  from  unheated  serum.  In  Series  C,  Table  V,  the
heating of the serum before the  salvarsan  was added resulted in pro-
ducing a more active mixture  than in Series A where the mixture was
not  subjected  to  heat.  But  the  action  of  the  mixture  in  Series  C
was not so strong  as in Series B where the two were heated together.
Series D demonstrated  that part of the effect of the heat was directly
upon the salvarsan,  for  although the heated  salvarsan was  combined
with  unheated  serum,  which  contained  inhibitory  substances,  the
mixture  was  more  spirocheticidal  than  the  unheated  mixture,  but
again  not so active as the heated  mixture.  That the  total  result  of
the heat is due to a summation of these two effects  is shown in Series
E  where  the  two  components  were  combined  after  heating.  This
mixture was stronger than either C or D and had practically  the same
effect  as  in  Series  B  where  the  two were  heated  together;  the  only
exception noted was in  Mouse E4 where  there was a very slight infec-
tion on the 3rd day.
The relative  effect  of  heat  upon  removal  of  inhibitory  substance
in the serum and upon increasing the spirocheticidal  action of salvar-
san was only slightly brought out in this experiment, where the infec-
tion  of Mouse  C4 was less  than that of D4; but in  two other similar
experiments,  in which  the controls  showed  a more  intense infection,
the  1:80,000  mouse in the C series was completely protected, while the
same mouse  in  the D  series showed distinct  infection.  The effect of
the heat seems,  therefore,  to be  relatively greater  in the  removal  of
inhibitory  substance  from  the  serum  than in directly increasing  the
activity of  the salvarsan.
380TABLE  V.
Effect  of Heat  on  Each  Component of the  Serum-Salvarsan Mixture.
Salvarsan
per  cc.  of
serum.
mg.
0.05
0.025
0.012
0.006
0.003
0.05
0.025
0.012
0.006
0.003
0.05
0.025
0.012
0.006
0.003
0.05
0.025
0.012
0.006
0.003
0.05
0.025
0.012
0.006
0.003
Heated  or unheated.
Unheated.
C'
Serum  and  salvar-
mixing.
Serum  heated,  sal-
varsan unheated.
I  Serum  unheated,
salvarsan heated.
Serum  and  salvar-
san  heated  sepa-
rately before mix-
ing.
Injected immediately.
Incubated with normal serum.
Day after  injection.
0
0
:a w
+
0
0
0
0
0
0
0
0
0
0
·- w
0
0
'*w
= w
0
0
0
0
+
+
+
2
0
0
+
+
++
0
0
0
0
+
0
0
0
0
0
0
+ 0
0
0
0
+
++
++
3
0
0
+
+
0
0
0
0
0
0
0
0
0
+
0
0
0
0
0
0
4
0
=Ew
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
The  serum  was from a patient  with cured (?) syphilis.  Wassermann  reaction
negative.  Series A and B were prepared  as in Table I.  In Series  C the serum was
heated at 560C. for  one-half hour and then the salvarsan was added and dilutions
were prepared.  In Series  D the salvarsan  (1: 2,000 dilution) was heated at 560C.
and then diluted with unheated serum.  At  the end of the period of heating the
salvarsan  was  only very  slightly turbid.  Portions  of  the heated serum  of Series
C and  heated  salvarsan  of Series D  after  heating  were  mixed in the  usual way.
The spirochetal  suspension, containing  between four and six  spirochetes per field,
was  mixed with the various  sera;  it was  then incubated  for  1 hour  and injected
into mice.
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Dilution of
salvarsan.
1:20,000
1:40,000
1:80,000
1: 160,000
1:320,000
1:20,000
1:40,000
1:80,000
1:160,000
1: 320,000
1:20,000
1:40,000
1:80,000
1: 160,000
1:320,000
1:20,000
1: 40,000
1: 80,000
1:160,000
1:320,000
1:20,000
1: 40,000
1: 80,000
1:160,000
1:320,000
Mouse.
Al
A2
A3
A4
A5
B1
B2
B3
B4
B5
C1
C2
C3
C4
C5
D1
D2
D3
D4
D5
El
E2
E3
E4
E5
Controls.
Si
S2
S
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
-- ￿-- ---- . . . _
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TABLE  VI.
Comparison of  Salvarsanized Serum with  Neosalvarsanized Serum.
Mouse.
Al
A2
A3
A4
B1
B2
B3
B4
B5
C1
C2
C3
C4
C5
D1
D2
D3
D4
D5
Control.
S1
S2
Dilution.
Salvarsan.
1:20,000
1: 40,000
1:80,000
1:160,000
1:20,000
1:40,000
1:80,000
1: 160,000
1:320,000
Neosalvarsan.
1:20,000
1:40,000
1:80;000
1:160,000
1:320,000
1:20,000
1:40,000
1:80,000
1:160,000
1: 320,000
Salvarsan
per  cc.  of
serum.
mg.
0.05
0.025
0.012
0.006
0.05
0.025
0.012
0.006
0.003
0.05
0.025
0.012
0.006
0.003
0.05
0.025
0.012
0.006
0.003
Heated or
unheated.
Unheated.
it
Heated.
it
it
Unheated.
Heated.
t
Heated.
Injected immediately.
After  1  hr.  incubation  with  normal
serum.
Day after  injection.
0
0
=w
0
0
0
0
0
0
0
0
0
= w
0
0
0
+
+
2
0
0
+
0
0
0
O
+
0
0
0
=I= w
++
0
0
0
0
";W
3
0
0
0
0
Dead.*
+
++
0
0
0
+
0
0
0
+
0
* Died from  mouse typhoid  infection.
Dilutions of salvarsan were made  in normal  serum in the  usual way.  Similar
dilutions of neosalvarsan in serum  were prepared,  0.15 gm.  of neosalvarsan  being
considered  the equivalent  of 0.1  gm.  of  salvarsan.  Each  dilution was  divided
into two portions, one of which was heated at 56°C. for one-half hour.  The spiro-
cheticidal  suspension, containing six to eight spirochetes  per field,  was mixed with
the sera; it was  then incubated and injected into mice.
In  comparing  the serum withdrawn from salvarsan- and  neosalvar-
san-treated  rabbits  on  successive  days  after  treatment,  Stiihmer4
4
0
0
0
0
0
0
0
0
0
0
0
0
+
0
0
0
0 0
0
0
I
. . -I-
....
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showed that the duration  of the trypanosomicidal  action of both was
practically  the same  if  the serum  was unheated,  and that  there was
but little difference  between  heated and unheated  serum  of  the neo-
salvarsan-treated  rabbits.  The  heated  serum  of  salvarsan-treated
rabbits,  however,  was trypanosomicidal  several  days longer  than  the
same  serum not heated.  He concluded,  therefore,  that heating  had
less  effect  on  neosalvarsanized  serum.  His method  of  experimenta-
tion did not lend itself to a comparative study of the effect of heating,
because  he  used  only  one  dilution  of  each  serum.  His  results  give
rather  the duration  of  trypanosomicidal  effect after  treatment,  and
the  comparative  rate  of  elimination  of  salvarsan  and  neosalvarsan.
Experiment  6  (Table  VI)  showed  that  neosalvarsan  is  more  active
against Spirochtcta duttoni than salvarsan,  but that heating increases
the action of both.  In each instance the spirocheticidal action of the
heated  serum  was  double  that of  the unheated.  Castelli7 similarly
showed  that neosalvarsan  was more  active  against  Spirochatta recur-
rentis than salvarsan,  the ratio being  1:600  to 1:400.  The  curative
dose  of  both  drugs  was  the  same  for  Spirochceta gallinarum, while
double  the dose  of  neosalvarsan,  compared  with  salvarsan,  was  re-
quired  to  cure  syphilis  in rabbits.  Thus  the comparative  curative
dose of the  two drugs  varies according  to the microorganism  tested.
This  experiment  proves  only  that heat  had  the same  relative  effect
on both salvarsan- and neosalvarsan-serum  mixtures.
The proof that a mixture  of salvarsan in normal serum had a defi-
nite  spirocheticidal  action  suggested  that  this  action  might  be  en-
hanced  if  the  salvarsan  were  mixed with  the  serum  of a  salvarsan-
treated patient.  The results of an experiment  to determine this point
are  shown in Table VII.  The lethal dose of the salvarsan in normal
serum for the spirochete was 0.012 mg.  The patient's serum (heated
at 56°C.) was  completely spirocheticidal  in a dilution  of  1: 1.  When
half  of this dilution was  mixed  with 0.006  mg.  of salvarsan  the mix-
ture was completely  spirocheticidal,  and even when the same amount
of  salvarsan  was  mixed  with  a  1:4  dilution  of  serum  only  a  slight
infection  of  the  mice  occurred.  Incidentally,  the  effect  of  heating
salvarsan-treated  patient's  serum  after it has stood 24 hours  is  well
7 Castelli,  G.,  Z. Chemotherap., Orig., 1913,  i,  321.
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TABLE  VII.
Effect  of Adding Salvarsan to the Serum of a Salvarsan-Treated  Patient.
Mouse.  Dilution  of  Salvarsan  per cc.  Heated or  Day after injection.
serum.  of serum.  unheated.
1  2  3  4
nag.
Normal.
B3  1:1  0.012  Heated.  0  0  Dead.*  -
B4  1:1  0.006  "  0  w  +  0
B5  1:1  0.003  w  +  ++  0
Patient's
serum.
El  1:1  0.006  "  0  0  0  0
E2  1:2  0.006  "  0  0  0  0
E3  1:4  0.006  "  w  -w  w  0
G1  1:1  None added.  0  0  0  0
G2  1:2  +  +  0
G3  1:4  +  +++  ++  0
HI  1:1  Unheated.  w  ++  +++  0
H2  1:2  +++  ++++  0
Control.
S1  Injected immediately.  +  ++  +  +  0
S2  1 :1  f After  1 hr.  incubation  with
normal serum.  +  +  ++  0  0
* Died from mouse typhoid infection.
Dilutions of salvarsan in normal  serum were made in the usual way and heated
(Series B).  A patient with tabes, weighing  70 kilos, received 0.35  gm. of salvar-
san  intravenously.  Blood was  withdrawn  one-half  hour later  and  allowed  to
stand  over night.  It  was  then centrifugalized  and  the  serum  pipetted off,  and
three series  of tubes, E, G, and H, were set up, and the serum was diluted with nor-
mal saline solution in Tubes  2 and 3.  To each of the tubes of Series E, 0.006 mg.
in 0.25  cc.  of normal serum was added,  after which  Series E and G  were heated
at 56°C.  for  one-half  hour.  The  spirochetal  suspension,  containing  six to eight
spirochetes per  field,  was  added to each tube;  it was then  incubated for  1 hour
and injected  into mice.
brought  out in the control series,  G  and H.  This  experiment  seems
to  prove  conclusively  that  the  most  potent  spirocheticidal  mixture
with  a given amount of  salvarsan is to be  expected from a combina-
tion  of  salvarsan with  the serum  of  a  salvarsan-treated  patient,  the
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blood  having  been  allowed  to  stand  over  night  before  the serum is
separated.
DISCUSSION.
Following  the introduction  of intraspinal  injection  of serum  in the
treatment  of  patients  with  syphilis  of  the  central  nervous  system,
numerous  workers  attempted  to  inject  intraspinally  salvarsan  or
neosalvarsan  in  weak  dilutions.  When  more  than  1 mg.  has  been
repeatedly  injected several  observers  have  noted  symptoms  of  my-
elitis in the lower  segment  of  the cord.  Marinesco and Minea8 have
observed that neosalvarsan  diluted with  serum is less irritating than
when  diluted with normal salt solution.  Fordyce,  and Ogilvie,2 who
have had  the greatest experience with the Ogilvie method of prepara-
tion  of  salvarsan  serum,  now advise  that only a fraction  of  a milli-
gram  of salvarsan  be mixed  with the serum for intraspinal injection.
Clinical evidence seems,  therefore, to indicate that only small amounts
of salvarsan  or neosalvarsan can be  safely injected into the subdural
space.  The  main  objection  to  subdural  therapy  of  cerebrospinal
syphilis  has  been  that  the  serum  injected  contained  such  small
amounts of salvarsan.  Obviously it is necessary  to keep the amount
of any  therapeutic  agent  below the injurious  dose.  Therefore,  with
the evidence at hand only small amounts  of the drugs at our disposal
can be  used.  Our object  then must  be  to use  them  in the least in-
jurious  and most potent  form.  From  the evidence  brought forward
in the experiments  in this communication, this would be the addition
of  small amounts  of  salvarsan  or neosalvarsan  to  the serum  of  sal-
varsan-treated  patients.  This serum preferably should be  allowed to
remain in contact with the clot over night, and should be heated after
the  addition  of  the  salvarsan.  Although  this  technique  is  compli-
cated, it could be easily carried out in clinics where  large numbers  of
patients  are  treated,  or  if  the  salvarsan  is  procurable  in  ampules
containing  small amounts,  so  that dilutions  for addition of the drug
to the serum might be economically prepared.
8 Marinesco,  G., and Minea,  J., Rev. neurol., 1914,  xxii, 337.
9 Fordyce,  J. A.,  J.  Am.  Med. Assn.,  1914,  lxiii,  552.SERUM  SALVARSANIZED  IN  VITRO
SUMMARY.
1. Addition of salvarsan to serum in vitro produces a spirocheticidal
mixture which is increased  in potency by heating.
2. The  heated  serum  of  salvarsan-treated  patients  is more  spiro-
cheticidal  if it has been in contact with the clot  over night than if it
has been  separated  immediately  after  coagulation.  This  is not true
with the serum from blood which has been salvarsanized  in vitro.
3.  The  addition  of  salvarsan  directly  to  serum  produces  a  more
potent  mixture  than  results  from  the  serum  from  blood  to which
salvarsan has been added  in equivalent amounts.
4.  The  increase  in  activity  of  salvarsanized  serum  produced  by
heating to 560C.  is due in part to the removal of inhibitory substances
in the serum and in part to a direct increase  in spirocheticidal  power
in the heated salvarsan.
5.  Both  salvarsanized  and  neosalvarsanized  serum  are  rendered
more spirocheticidal  by heating.
6.  A  more  active  spirocheticidal  mixture  is  produced  by  mixing
small  amounts  of  salvarsan  with  the  serum  of  a  salvarsan-treated
patient than by mixing the same amount with normal serum.
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